Avenue Therapeutics (ATXI) Expected to Announce Earnings on Wednesday

Avenue Therapeutics (NASDAQ:ATXI) is projected to release its results after the market closes on Wednesday, May 13th. Analysts expect Avenue Therapeutics to post earnings of ($56.25) per share for the quarter.

Avenue Therapeutics Stock Down 20.0%

Shares of Avenue Therapeutics stock opened at $0.52 on Wednesday. The firm has a market cap of $1.71 million, a price-to-earnings ratio of 0.03 and a beta of -0.09. The business has a fifty day simple moving average of $0.36 and a 200-day simple moving average of $0.52. Avenue Therapeutics has a fifty-two week low of $0.15 and a fifty-two week high of $0.97.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for disorders of the central nervous system, with an initial emphasis on acute pain management. The company’s research and development efforts are centered on reformulating established active pharmaceutical ingredients to address unmet needs in hospital and outpatient settings, aiming to improve safety profiles, reduce opioid exposure and support enhanced patient recovery.

The company’s lead product candidate is intravenous tramadol, a unique non-solicited opioid analgesic that combines dual mechanisms of action to manage moderate to severe acute pain.